Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

24.17 +0.07 (+0.29%)
Streaming Delayed Price Updated: 12:39 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 516,764
Open 24.04
Bid (Size) 24.15 (4)
Ask (Size) 24.19 (1)
Prev. Close 24.10
Today's Range 24.01 - 25.47
52wk Range 16.95 - 49.50
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO: 
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... 
Via Benzinga

Performance

YTD
-11.82%
-11.82%
1 Month
-28.26%
-28.26%
3 Month
-2.38%
-2.38%
6 Month
+26.54%
+26.54%
1 Year
-20.78%
-20.78%

More News

Read More
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Beam Therapeutics
Via GlobeNewswire
Navigating 4 Analyst Ratings For Beam Therapeutics
Via Benzinga
Recap: Beam Therapeutics Q4 Earnings
Via Benzinga
MarketBeat Week in Review – 3/4 – 3/8
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Via MarketBeat
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Via Investor's Business Daily
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Via Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Is CRISPR Therapeutics the NVIDIA of gene editing?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
Via Investor's Business Daily
Analysts see over 50% gains in these 2 mid-cap biotech stocks
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
Via Benzinga
3 Biotech Stocks to Buy on the Dip: February 2024
Via InvestorPlace
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Beam Therapeutics
Via GlobeNewswire
Why Beam Therapeutics Stock Zoomed 17% Higher Today
Via The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
Via MarketBeat
Exposures Product Safety
Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K
Via Benzinga
Topics ETFs
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Via InvestorPlace
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.